Integrated Research Institute for Natural Ingredients and Functional Foods
Yangsan, 50612, South Korea
Location status: Recruiting
NCT Number: NCT03775837
The investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of Panax Ginseng C.A. Mey Extract on liver function in adults for 8 weeks.
Interested in participating?
Request Info19 year–75 year
All sexes
Interventional
Not applicable
Yangsan, 50612, South Korea
Location status: Recruiting
Previous studies have indicated that Panax Ginseng C.A. Mey Extract may have the ability to improve liver function. Therefore, the investigators conduct a randomized, double-blind, placebo-controlled study to investigate the effects of the Panax Ginseng C.A. Mey Extract on liver function in adults; the safety of the compound are also evaluate. The Investigators examine AST, ALT, GGT, and other metabolic parameters at baseline, as well as after 4 and 8 weeks of intervention. Sixty adults were administered either 600 mg of Panax Ginseng C.A. Mey Extract or a placebo each day for 8 weeks;
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
This group takes placebo for 8 weeks
Time frame: 8 weeks
Alanine aminotransferase
Time frame: 8 weeks
Aspartate aminotransferase
Time frame: 8 weeks
Gamma-glutamyl transferase
Interested in participating?
Request InfoPusan National University Yangsan Hospital
Other
Effect of Panax Ginseng C.A. Mey Extract on Liver Function in Adults: a Randomized, Double-blinded, Placebo-controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03813862
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Durham, North Carolina, United States
View Trial DetailsNCT07400289
Digestive System Diseases, Liver Diseases
Besançon, France
View Trial DetailsNCT06519331
Digestive System Diseases, Liver Diseases
Orsay, France
View Trial DetailsNCT04181138
Bile Duct Diseases, Biliary Tract Diseases
Los Angeles, California, United States
View Trial Details